Brain Tumor
Conditions
Keywords
Brain Tumor, Inflammation, Procalcitonin, CRP, NLR
Brief summary
This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance
Detailed description
This study is a case controlled analytical study to find the relationship between levels of inflammatory markers in patients with brain tumors. Samples were collected from patients at Haji Adam Malik Hospital in Medan, then the patient's blood serum was taken to be checked for these variables. Sample collection began in March - September 2020. The sample obtained was 35 people who met the inclusion and exclusion criteria. Inclusion criteria: 1. Willing to be a sample 2. Complete medical records 3. Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor Exclusion criteria: 1. The patient's age is over 70 years 2. Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others 3. Patients with a history of brain tumor surgery or previous brain tumor treatment Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically. Based on this analysis, it will be determined whether there is a significant relationship between levels of inflammatory markers in the incidence of brain tumors.
Interventions
DIAGNOSTIC_TESTProcalcitonin
Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
Sponsors
Universitas Sumatera Utara
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Willing to be a sample 2. Complete medical records 3. Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor
Exclusion criteria
1. The patient's age is over 70 years 2. Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others 3. Patients with a history of brain tumor surgery or previous brain tumor treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Value of Procalcitonin | February-April 2020 | Value of Procalcitonin in each group (Meningioma Group, Glioma Group and Brain metastasis group) |
| Value of C-Reactive Protein | April- June 2020 | Value of C-Reactive Protein in each group (Meningioma Group, Glioma Group and Brain metastasis group) |
| Value of Neutrophyl to Lymphocyte Ratio (NLR) | June- August 2020 | Value of NLR in each group (Meningioma Group, Glioma Group and Brain metastasis group) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Demographic of samples | August- October 2020 | Demographic of each samples such as age, gender, Glassgow coma scale and Karnofsky score |
Countries
Indonesia
Outcome results
None listed